These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30920617)

  • 1. Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Jpn J Clin Oncol; 2019 May; 49(5):473-476. PubMed ID: 30920617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
    N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in medical therapy for metastatic urothelial cancer.
    Yuasa T; Urakami S; Yonese J
    Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
    Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
    J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
    Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
    Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.
    Kobayashi K; Suzuki K; Hiraide M; Aoyama T; Yokokawa T; Shikibu S; Hashimoto K; Iikura Y; Sato H; Sugiyama E; Tajima M; Hama T
    Oncology; 2020; 98(4):237-242. PubMed ID: 31935736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab as second-line treatment for urothelial cancer.
    Mitchell F
    Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
    [No Abstract]   [Full Text] [Related]  

  • 10. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
    Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
    Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.
    Yasuoka S; Yuasa T; Nishimura N; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
    Anticancer Res; 2019 Jul; 39(7):3887-3892. PubMed ID: 31262917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
    Hunter L; Moser J; Sturge C; Barraza G; Colonna S
    J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
    Tsimafeyeu I; Tjulandin S
    BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
    [No Abstract]   [Full Text] [Related]  

  • 15. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
    Rexer H; Ohlmann CH; Retz M
    Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma].
    Wilborn D; Schmidt S
    Urologe A; 2019 Jan; 58(1):45-48. PubMed ID: 30560284
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
    Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.
    Ji Z; Peng Z; Gong J; Zhang X; Li J; Lu M; Lu Z; Shen L
    BMC Cancer; 2019 Jul; 19(1):705. PubMed ID: 31315610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.